Development and validation of a single robust HPLC method for the characterization of a pharmaceutical starting material and impurities from three suppliers using three separate synthetic routes.
Novel approaches to the development of analytical procedures for monitoring incoming starting material in support of chemical/pharmaceutical processes are described. High technology solutions were utilized for timely process development and preparation of high quality clinical supplies. A single robust HPLC method was developed and characterized for the analysis of the key starting material from three suppliers. Each supplier used a different process for the preparation of this material and, therefore, each suppliers' material exhibited a unique impurity profile. The HPLC method utilized standard techniques acceptable for release testing in a QC/manufacturing environment. An automated experimental design protocol was used to characterize the robustness of the HPLC method. The method was evaluated for linearity, limit of quantitation, solution stability, and precision of replicate injections. An LC-MS method that emulated the release HPLC method was developed and the identities of impurities were mapped between the two methods.
Sheldon
E M
EM
Monsanto, Searle, Chemical Sciences Analytical Department, Skokie, IL 60077, USA. edward.m.sheldon@monsanto.com
Downar
J B
JB
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D013058:Mass Spectrometry; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000302:isolation & purification; D013056:Spectrophotometry, Ultraviolet
D004364:Pharmaceutical Preparations